Summit Therapeutics Inc.
NGM: SMMTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Summit Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SMMT Z-Score →About Summit Therapeutics Inc.
Healthcare
Biotechnology
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
📊 Fundamental Analysis
Summit Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -206.1%, which indicates that capital utilization is currently under pressure.
At a current price of $19.67, SMMT currently sits at the 25th percentile of its 52-week range (Range: $13.83 - $36.91).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$15.25B
Trailing P/E
--
Forward P/E
-16.75
Beta (5Y)
-1.37
52W High
$36.91
52W Low
$13.83
Avg Volume
2.55M
Day High
Day Low